Search

Learn about some of the most important advances in cancer treatment at MSK in 2025.

… Monday, December 15, 2025 Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in a variety of cancer treatments in 2025 — including new approaches to immunotherapy, targeted therapy, and surgical imaging. Highlights this year also included a stem cell–based therapy for Parkinson

New research from Sloan Kettering Institute investigators pinpoints altered cell metabolism as a cause of B cell lymphoma.

… Monday, June 22, 2020 Summary Scientists at the Sloan Kettering Institute have found that increased activity of a normal metabolic enzyme can lead to cancer. The enzyme, SHMT2, is a driver of a large portion of B cell lymphomas and could be a potential drug target. Because of how aggressively they divide

Research from investigators at the Sloan Kettering Institute shows how a brain circuit controls mating behavior in fruit flies.

… Thursday, June 25, 2020 Summary Sloan Kettering Institute scientists have discovered how a genetic switch in the brain controls mating behavior in female fruit flies. The insights contribute to scientists’ understanding of fundamental neurobiological processes, including those that may go awry in disease

Get tips from a Memorial Sloan Kettering dietitian if you’ve completely lost your appetite during cancer treatment.

… Thursday, October 17, 2019 Summary A Memorial Sloan Kettering expert offers strategies to help people with cancer who feel like they can’t eat anything. In the Kitchen CancerSmart: In the Kitchen with MSK Learn more Getting proper nutrition during cancer treatment is vital. As the body tries to cope

… Thursday, April 6, 2023 Memorial Sloan Kettering Cancer Center (MSK) researchers have discovered that innate immune signaling drives late cardiac toxicity after DNA-damaging cancer therapies. Their results, published in the Journal of Experimental Medicine on March 6, 2023, identify a targetable mechanism

June’s “MSK Science Spotlight” segments kick off on Monday, June 1, featuring the honoree of the Katharine Berkan Judd Award Lectureship, Ron Vale, PhD, Vice President and Executive Director, Janelia Research Campus at the Howard Hughes Medical Institute.

… Monday, June 1, 2020 June’s “ MSK Science Spotlight ” segments kick off on Monday, June 1, featuring the honoree of the Katharine Berkan Judd Award Lectureship, Ron Vale, PhD, Vice President and Executive Director, Janelia Research Campus at the Howard Hughes Medical Institute. Dr. Vale will be presenting

Adding immunotherapy to standard treatment both before and after surgery significantly improved outcomes for people with gastric and gastroesophageal adenocarcinoma (G/GEA), according to experts from Memorial Sloan Kettering Cancer Center (MSK). Results from the MATTERHORN trial, a global phase three study, were presented today at the annual American Society of Clinical Oncology meeting and simultaneously published in the New England Journal of Medicine (NEJM).

… Sunday, June 1, 2025 Adding immunotherapy to standard treatment both before and after surgery significantly improved outcomes for people with gastric and gastroesophageal adenocarcinoma (G/GEA), according to experts from Memorial Sloan Kettering Cancer Center (MSK). Results from the MATTERHORN trial,

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health is funding a research collaboration among six institutions in close alliance. The total funding, provided by the National Institute of Allergy and Infectious Diseases, could be up to $45.7 million over seven years.

… Wednesday, February 18, 2015 In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health has awarded Weill Cornell Medical College more than $6.2 million in first-year funding to support a research collaboration among six institutions

Lymphoma experts Anas Younes, MD and Andrew Zelenetz, MD, PhD discuss the fast evolving research on CAR T cells and checkpoint inhibitors that is yielding the novel treatment options improving both outcomes and quality of life for people with lymphoma.

… Wednesday, May 16, 2018 VIDEO | 05:17 Lymphoma Update: CAR T Therapies and Checkpoint Inhibitors Lymphoma experts Anas Younes, MD and Andrew Zelenetz, MD, PhD discuss the fast evolving research on CAR T cells and checkpoint inhibitors that is yielding the novel treatment options improving both outcomes

A new MSK-led study used single-cell sequencing and other techniques to examine a phenomenon known as “whole-genome doubling” in high-grade serous ovarian carcinoma (HGSOC), the most common and aggressive form of ovarian cancer. The insights could help researchers develop more effective treatment strategies.

… Wednesday, July 16, 2025 Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves — insights that could help researchers develop more effective treatment strategies. While ovarian cancer diagnoses and deaths have decreased over recent decades ,